Sai Life Sciences Limited is preparing to launch its IPO. The IPO will open on 11 December 2024 (Wednesday) and will close on 13 December 2024 (Friday). This is a book-built issue IPO. Through this issue the company is going to raise from potential investors approximately ₹3,042.62 crores.
The IPO consists of a fresh issue of 17,304,189 equity shares amounting to ₹950 crores and an offer for sale of 38,116,934 equity shares amounting to ₹2,092.62 crores. The face value of the shares is ₹1 per share, and the price band is set between ₹522 and ₹549 per share. Investors can bid for a minimum lot size of 27 shares.
IPO Key Highlights
| Category | Detail | Information |
|---|---|---|
| Key Dates | IPO Open Date | December 11, 2024 |
| IPO Close Date | December 13, 2024 | |
| Pricing Information | Face Value | ₹1 per share |
| Price Band | ₹522 to ₹549 per share | |
| Offer Structure | Total Issue Size | 55,421,123 shares (amounting up to ₹3,042.62 Cr) |
| Fresh Issue | 17,304,189 shares (amounting up to ₹950.00 Cr) | |
| Offer for Sale | 38,116,934 shares (amounting up to ₹2,092.62 Cr) | |
| Investor Details | Lot Size | 27 Shares |
| Listing Exchange | BSE and NSE | |
| IPO Type | Book Built Issue IPO |
Important Dates to Remember
| Event | Date |
|---|---|
| IPO Opening Date | 11 December 2024 (Wednesday) |
| IPO Closing Date | 13 December 2024 (Friday) |
| Finalisation of Basis of Allotment | 16 December 2024 (Monday) |
| Initiation of Refunds | 17 December 2024 (Tuesday) |
| Credit of Shares to Demat Account | 17 December 2024 (Tuesday) |
| Listing Date | 18 December 2024 (Wednesday) |
What is GMP of Sai Life Sciences IPO Today?
As of December 10, 2024, the Grey Market Premium (GMP) for the Sai Life Sciences IPO is ₹28. This indicates that the shares are expected to list at approximately ₹577 per share.
Note: GMP is an unofficial indicator and is based on market speculation; it does not guarantee actual listing performance.
Company Financials
| Period | 30 Sep 2024 (₹ Crore) | 31 Mar 2024 (₹ Crore) | 31 Mar 2023 (₹ Crore) | 31 Mar 2022 (₹ Crore) |
|---|---|---|---|---|
| Total Assets | 2,476.78 | 2,275.14 | 2,186.65 | 2,164.23 |
| Total Revenue | 693.35 | 1,494.27 | 1,245.11 | 897.74 |
| Total Expense | 656.09 | 1,385.04 | 1,228.70 | 888.05 |
| Profit After Tax | 28.01 | 82.81 | 9.99 | 6.23 |
| Company’s Net Worth | 1,044.75 | 974.34 | 887.29 | 877.76 |
| Total Reserves & Surplus | 855.69 | 953.99 | 867.43 | 859.17 |
Sai Life Sciences Limited has shown a consistent growth in its total assets, increasing from ₹2,164.23 crores in FY 2022 to ₹2,476.78 crores as of 30 September 2024. It shows that the company is making efforts for the expansion and making investment in its operational capabilities.
The company’s total revenue has shown a consistent upward trend, it has been increased from ₹897.74 crores in FY 2022 to ₹1,494.27 crores in FY 2024. This highlights the company’s ability to maintain growth despite industry challenges.
Sai Life Sciences has significantly improved its Profit After Tax . It has increased from ₹6.23 crores in FY 2022 to ₹82.81 crores in FY 2024.
Company’s Key Metrics (FY 2024)
| Key Performance Indicator | Value |
|---|---|
| Return on Capital Employed (ROCE) | 10.26% |
| Return on Equity (ROE) | 8.49% |
| EBITDA Margin (%) | 20.48% |
| After Tax Profit Margin (%) | 5.65% |
| Debt to Equity Ratio | 0.75 |
| Return on Net Worth (RONW) | 8.50% |
| Net Asset Value (NAV) | ₹53.83 |
| Earnings Per Share (EPS) | ₹4.57 (Basic) |
Lot Size and Application Amount
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail Investor (Minimum Lot) | 1 | 27 | ₹14,823 |
| Retail Investor (Maximum Lot) | 13 | 351 | ₹192,699 |
| Small HNI Investor (Minimum Lot) | 14 | 378 | ₹207,522 |
| Small HNI Investor (Maximum Lot) | 67 | 1,809 | ₹993,141 |
| Big HNI Investor (Minimum Lot) | 68 | 1,836 | ₹1,007,964 |
Investor Category-Wise Reservation
| Investor Category | Reservation |
|---|---|
| Shares Reserved for QIB | Not more than 50% of the Net Offer |
| Shares Reserved for Retail Investors | Not less than 35% of the Net Offer |
| Shares Reserved for Non-Institutional Investors | Not less than 15% of the Net Offer |
Net Cash Flow Overview
| Net Cash Flow | For the Period Ended 30 September 2024 (₹ in millions) | FY 2024 (₹ in millions) | FY 2023 (₹ in millions) | FY 2022 (₹ in millions) |
|---|---|---|---|---|
| Net Cash Flow from Operating Activities | 1,013.61 | 2,630.87 | 2,194.03 | 1,048.66 |
| Net Cash Flow from Investing Activities | -1,075.56 | -1,923.81 | -1,017.81 | -1,037.14 |
| Net Cash Flow from Financing Activities | 247.85 | -952.99 | -2,006.48 | 719.23 |
| Net Increase/(Decrease) in Cash and Cash Equivalents | 185.90 | -245.93 | -830.26 | 730.75 |
Peer Comparison: EPS, PE Ratio, and Face Value
| Company Name | EPS* Basic (₹) | P/E Ratio | Face Value (₹) |
|---|---|---|---|
| Sai Life Sciences Limited | 4.57 | NA | 1.00 |
| Syngene International Limited | 12.71 | 73.59 | 10.00 |
| Suven Pharmaceuticals Limited | 11.80 | 109.37 | 1.00 |
| Divi's Laboratories Limited | 60.27 | 103.0 | 2.00 |
Key Objectives of this Issue
The fund raised through this issue will be utilized for the following purposes.
- Repayment or Prepayment of Borrowings
- Funding Capital Expenditure Requirements
- Investment in Research and Development Initiatives
- Meeting Working Capital Needs
- General Corporate Purposes
Positives and Negatives of Company
Positives:
- Experienced and Skilled Leadership Team
- Commitment to Research and Innovation
- Robust Financial Performance
- Advanced Infrastructure and Facilities
- Global Regulatory Compliance and Approvals
- Renowned and Diversified Clientele
Negatives
- High Dependency on few Clients
- Huge Borrowings and Financial Obligations
- Vulnerability to Market and Economic downturns
- Limited Geographic Diversification
- Intense Competition in the Industry
It is always beneficial to read Draft Red Herring Prospectus (DRHP) and Red Herring Prospectus (RHP) carefully to better understand its financials and growth opportunities before making a decision.
Looking for more IPO reviews? Check out our IPO Dashboard for recent posts on other Main-board IPO & SME IPOs for the latest market updates.
Popular Questions about this IPO
1. What are the opening and closing dates for the Sai Life Sciences IPO?
The IPO opens on December 11, 2024, and closes on December 13, 2024.
2. Who are the lead managers for this IPO?
The lead managers are Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited (Formerly known as IIFL Securities Limited), Jefferies India Private Limited, and Morgan Stanley India Company Private Limited.
3. Who is the registrar for the Sai Life Sciences IPO?
The registrar is KFin Technologies Limited.
4. What is the issue price for the Sai Life Sciences IPO?
The issue price is set between ₹522 and ₹549 per equity share.
5. What is the minimum lot size for retail investors in this IPO?
Retail investors can bid for a minimum of 27 shares, amounting to ₹14,823.
6. What are the main objectives of the IPO?
The funds raised through this issue will be utilized for repayment/prepayment of certain borrowings, funding capital expenditure, and other general corporate purposes.
7. On which stock exchanges will the shares be listed?
The shares are proposed to be listed on BSE and NSE.
8. What is the total issue size for the Sai Life Sciences IPO?
The IPO consists of 55,421,123 equity shares, amounting to ₹3,042.62 crores.
9. When will the allotment and refund process begin?
Allotment will begin on December 16, 2024, and refunds will start soon after.
10. When will the shares be credited to the Demat account?
Shares will be credited to investors’ Demat accounts on December 17, 2024.
11. What is the expected listing date for the IPO?
The shares are expected to list on December 18, 2024.
Note: This article is based on the information received from the company’s official documents, including the Draft Red Herring Prospectus (DRHP) and Red Herring Prospectus (RHP). For up-to-date information on the Grey Market Premium (GMP) for the Sai Life Sciences IPO, you may please check our Current GMP, where we will post the latest figures as soon as they are available.
Disclaimer: This article is for educational purposes only. We do not offer any advice on buying or selling securities. Please consult your financial advisor before investing in an IPO or any other securities to make sure that it suits your financial plans and risk tolerance.
Don’t miss out on the latest IPOs – Click here to Find Upcoming IPOs.
“Invest Smarter, Faster – Click Here to Open Your Free Demat Account Today!”
“If this article was useful to you, feel free to share it with others who might find it helpful. Your feedback is important, so drop your questions or thoughts in the comments—we’d love to hear from you!”
Looking for the latest updates on upcoming IPOs? Explore detailed insights, expert reviews, and key information on these trending IPOs:
Leave a comment